Showing 8341-8350 of 8879 results for "".
- SCCA Doctors Address the Future of Immunotherapy for Melanomahttps://practicaldermatology.com/news/scca-doctors-address-the-future-of-immunotherapy-for-melanoma/2458600/Immunotherapy is the hottest topic in cancer care today, and metastatic melanoma is among the first type to benefit from this fourth cancer therapy. Two Seattle Cancer Care Alliance (SCC
- SPF30 Sunscreens Delay Melanoma Onset in Mouse Modelhttps://practicaldermatology.com/news/spf30-sunscreens-delay-melanoma-onset-in-mouse-model/2458601/Applying sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B (UVB) light delayed melanoma onset in a mouse model, report researchers from The Ohio State University Comprehensive Cancer Center Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. S
- Recent AAD Meeting Boasts Record Attendancehttps://practicaldermatology.com/news/recent-aad-meeting-boasts-record-attendance/2458607/More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 educational sessions, during
- Psoriasis Market Poised for Growth Spurt by 2024https://practicaldermatology.com/news/psoriasis-market-poised-for-growth-spurt-by-2024/2458609/The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria
- Pfizer-AGN Deal Offhttps://practicaldermatology.com/news/all-eyes-on-pfizer-agn-deal-is-it-doa/2458617/UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses associated with the transaction. Dublin-based Allergan reiterates in the statement its growth opport
- FDA Approves Inflectra, a Biosimilar to Remicadehttps://practicaldermatology.com/news/fda-approves-inflectra-a-biosimilar-to-remicade/2458618/And then there were two ... The U.S. Food and Drug Administration approved the biosimilar Inflectra (infliximab-dyyb) for multiple indications. Inflectra is biosimilar to Janssen Biotech, Inc.&rsq
- Melanoma Cells Grow More Aggressive with Agehttps://practicaldermatology.com/news/melanoma-cells-grow-more-aggressive-with-age/2458622/Aged tumor cells in melanoma tend to be metastatic and more resistant to treatment compared with younger tumor cells, according to an international team led by researchers out of The Wistar Institute in Philadelphia. The findings, which appear in
- Galderma, Mentor Worldwide, LLC Set to Collaboratehttps://practicaldermatology.com/news/galderma-mentor-worldwide-llc-set-to-collaborate/2458623/Galderma and Mentor Worldwide LLC, are joining forces to increase awareness and provide a broader range of offerings to healthcare providers and patients seeking aesthetic injectable treatments and breast enhancement. Data shows up to 33% of women
- Tissue Regeneration Leader Takes Home 2016 Furumoto Award at ASLMS 2016https://practicaldermatology.com/news/tissue-regeneration-leader-takes-home-2016-furumoto-award-at-aslms-2016/2458627/Praveen Arany, DDS, PhD will receive the 2016 ASLMS Dr. Horace Furumoto Innovations Young Investigator Award during the Plenary Session at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS).